Try our Advanced Search for more refined results
Life Sciences - December, 2015
249 articles
- Life Sciences Legislation And Regulation To Watch In 2016
- Life Sciences Cases To Watch In 2016
- 'Unicorn' Tech Co.'s $200M Deal Leads Pipeline Of 4 IPOs
- Fed. Circ. Won't Rethink $4M IP Verdict Against Globus
- Injunction On 'Gray Market' Abbott Diabetes Test Strips Grows
- 3 Things To Expect From Legal Tech In The New Year
- SAC To Pay $10M To End Investors' Trading-Fraud Suit
- Transport Cos. Can't Sink AXA's Suit Over $9M Drug Theft
- Del. Justices Uphold $195M Award To PharmAthene
- Canada Says Lilly Seeks 'Uber-Tribunal' In $500M IP Fight
- Valeant Faces Contact Lens Antitrust Class Action
- Actavis Says Namenda Product-Hopping Suit Has No Hop
- Generic Paxil Flap Ends Without Explanation
- Pelvic Mesh Plaintiff Wants $1.2M Ethicon Win Restored
- Novartis Unit Settles Sex Bias Suit For $8M
- Genelux Avoids Contempt Ruling In Chancery For Now
- Trade Groups Back Warner Chilcott In 3rd Circ. Doryx Row
- Kentucky AG Settles OxyContin, Risperdal Suits For $39.5M
- A Concession For ACA Medical Device Tax Opponents
- What To Know About Patent Reform Bills Heading Into 2016
- Celgene Allows Earlier Cancer Drug Generic In Patent Deal
- Judge Signs Off On $9M Skelaxin Antitrust Settlement
- Drug Cos. Ask 3rd Circ. To Halt Trial For Class Cert. Fight
- Boston Scientific Can't Get Fees From Blank Rome DQ
- Deals Rumor Mill: Shire, Caverion, ConocoPhillips
- Consumers Seek To Pause Pfizer Exit From Testosterone Suit
- Physician Assistant Gets 42 Months In Test-Referral Scheme
- Novartis Seeks Too Much In Attys' Fees In IP Row, NPE Says
- Supplement Co. Says Rivals' Products Use Steroid-Like Drugs
- Robbins Geller Looks To Lead Valeant Securities Fraud Suit
- Kaye Scholer Atty Charged In Shkreli Case Can Go To Cancun
- FDA Warning Wire: Sun Pharma, Device Changes, Food Filth
- New Evidence Backs Experts In Fixodent MDL, Consumers Say
- Ex-Oriole Can't Nix Insider Trading Evidence At 9th Circ.
- Ex-Steris Worker Backs Out Of Tainted Goods Suit
- In Congress: A Year-End Review
- Fosamax Users Rip Merck's Fracture Warnings In 3rd Circ.
- J&J Tagged With $7M Punitives In Pa. Pelvic Mesh Case
- FCA In 2015: 10 Qui Tam Highlights From The Past Year
- A Look At Martin Shkreli's Legal Woes
- The Role Of Previously Considered Prior Art In Instituting IPR
- Planting The Seeds For IP Protection Of Marijuana Brands
- Calif. Judge Transfers Teva Painkiller Suits To Kentucky
- Deals Rumor Mill: Lyft, Dermapharm, Greybull Capital
- Feds Urge High Court To Nix Enhanced Patent Damages Test
- Genelux Founder Pushes Chancery To Find Co. In Contempt
- Disputed IP Rights Properly Awarded To Biotech Co.: Judge
- Mass. Hospital Operator Slaps Rival With Monopoly Suit
- Group Says Aveeno 'Natural' Label Common In False Ad Suit
- Martin Shkreli Fired From KaloBios Post, Sued By Investors
- Walgreens Pushes Lipitor Pay-For-Delay Row At 3rd Circ.
- J&J Found Liable In 1st Philly Pelvic Mesh Case
- OrbiMed Launches $950M Venture Capital Fund
- The Firms That Dominated In 2015
- Law360 Names Practice Groups Of The Year
- Why All US Attorneys Should Read Justice Breyer's New Book
- Merck Ruling A Wake-Up Call For Patent Owners Facing PTAB
- Warner Chilcott To Pay $23M To End Calif. Fraud Claims
- Risperdal Victim Asks Pa. Judge For New Damages Trial
- Shkreli Leaves Turing Pharma As New CEO Tapped
- 10th Circ. Denies Marijuana Co. Appeal Of Tax Info Order
- Pfizer Should Face Lipitor Row In Calif., 3rd Circ. Hears
- Deals Rumor Mill: Syngenta, First Quantum, Apollo Global
- NJ Court Won't Ax Ironridge Global Suit Over Pharma Stocks
- Pharma Groups Urge Justices To Revive $18M Fine In IP Row
- Kaye Scholer Follows Crisis Blueprint After Lawyer's Arrest
- Consumers In Aveeno 'Natural' False Ad Suit Seek Cert.
- PTAB Shuts Down Another Bass AIA Review Of Horizon Drug
- FTC Tells High Court To Nix Boehringer's Appeal In Doc Row
- Axinn Veltrop Adds IP Attys From Arent Fox, Par Pharma
- Weight Loss Drug Maker Latest To Pull IPO Amid Weak Market
- Plastic Microbead Ban Heads To Obama For Signature
- Whistleblower Sues Hearing Aid Nonprofit After Being Fired
- Genzyme Asks Fed. Circ. To Revive Muscle Treatment Patents
- Allergan Wins Stay Of Infringement Suit Pending Patent Review
- Ex-Warner Chilcott Exec Prods Feds For Witness Info
- Senate Passes $1.8T Spending And Tax Extender Package
- The 13 Hottest Patent Law Issues Of 2015
- Shkreli, Kaye Scholer Atty Give Gov't Gift Of Shady Emails
- Warner Chilcott Defends Dismissal Of Doryx Case In 3rd Circ.
- Mylan, Ranbaxy Can't Halt Pay-For-Delay Suits Pending Appeal
- Kaye Scholer Atty, Shkreli May Not Enjoy Privilege For Long
- Merck Can't Save Patents In 1st Fed Circ. Pharma AIA Appeal
- BigLaw's Latest Bad Boy Built Colorful Career On Bitcoin
- Endo Health Faces Consumer Suit Over Flouride Labeling
- Jurors Prepare To Mull First Philly Pelvic Mesh Case
- Fla. High Court OKs Medical Marijuana Ballot Initiative
- AstraZeneca To Pay $4B For Cancer Treatment Developer
- The Biggest NJ Decisions From The Second Half Of 2015
- House Passes Sweeping $622B Tax Extenders Bill
- Amarin, FDA Off-Label Promotion Suit Stayed Until Feb.
- Pharma Bad Boy Martin Shkreli, Kaye Scholer Partner Arrested
- Calls For Bigger Patent Awards 'Disastrous,' Justices Told
- Endo Pays $39M To End Whistleblower's Fluoride Tablet Suit
- How Much Control Of Your Contracts Do You Really Have?
- Smith & Nephew Hip Implant Suit Survives Some Preemption
- NJ Plavix Suit Stayed Pending Supreme Court FCA Ruling
- Anda Not Covered In Drug 'Epidemic' Suit, 11th Circ. Told
- Purdue Takes Another Shot At Amneal Over OxyContin Generic
- Impossibility Preemption Possible For Brand-Name Drugs
- Lawmakers Reach Deal On Massive Tax Benefits Package
- Provigil Buyers' Per Se Theory Nixed In Pay-For-Delay Row
- Orrick Lands Weil Gotshal Life Sciences Ace In NY
- Acorda Blasts Bass-Backed Group's Bid To Nix Drug Patents
- SIGA Strikes PharmAthene Deal, Files Ch. 11 Plan
- Fla. Med. Marijuana Amendment Marches Toward 2016 Ballot
- Par Pharma Can't Get 2nd Fed. Circ. Win Over AIDS Drug
- Bio-Rad Denied Quick Appeal In Whistleblower GC's Suit
- UK Watchdog Probes OTC Pain Medicine Ads
- Allergan Loses Latest Bid To Nix Botox Price-Fixing Suit
- Supplement Co. Faces Sanctions Bid In Wal-Mart False Ad Row
- Customers Lose Cert. Bid In Lead-Laced Supplement Row
- FDA Warning Wire: Compounders, Supplements, Dirty Cheese
- Deals Rumor Mill: ChemChina, Saks Fifth Ave., Advance Auto
- Enzymotec Can't Shake Shareholder Suit Over $70M IPO
- Pacira Settles With FDA Over Pain Drug's Off-Label Uses
- DC Circ. Questions If $460M Czech Arbitration Row Is Moot
- 3 Things Baby Boomers Can't Stand About Young Lawyers
- Shoddy Hemorrhoid Stapler Sticks J&J Unit With $80M Verdict
- FTC To Get Its Mitts On AbbVie Docs In Pay-For-Delay Suit
- 7 Deadly Business Mistakes That Can Tank Your Law Practice
- Judge Unsure Whether To Remand Cherokees' Risperdal Suit
- Lifewatch Disclaims Telemarketing Scam At Trial With FTC
- Fla. Cannabis Growers Challenge Licensing Decisions
- NJ Plant Workers Hit Merck With FLSA Class Action
- Janssen Sued Over Diabetes Drug's Blood Disorder Risk
- Insys Blasts Coalition's Bid To Invalidate Painkiller Patents
- 3M Warming Device Infection Suits Grouped In Minn.
- Hyland's Says False Advertising Class Can't Change Argument
- J&J Hit With Class Suit Alleging FCRA Violations
- Ethicon Says Bulk Demand For Mesh Records Is 'Burdensome'
- Trends In Responsible Corporate Officer Doctrine Under FDCA
- Jaw Disease Patient's Novartis Suit Timely, 9th Circ. Hears
- Novartis Jaw Injury Suit Years Too Late, Judge Says
- Calif. Woman Wins Almost $10M In Ethicon Stapler Suit
- FDA Approves Genentech's Advanced Lung Cancer Drug
- 6th Circ. Cements J&J Win In Ortho Evra Blood Clot Suit
- FTC Asks Walgreens, Rite Aid For Info On $17.2B Merger
- Deals Rumor Mill: Pharmaceutical Product, GoPro, Quartz
- Give Judges Free Hand To Hike Patent Awards, Justices Told
- Steris Loss Won't Change FTC Merger Tactic, Ex-Official Says
- Celgene, Astellas Sue Teva Over Cancer Drug Patents
- AbbVie Targets Dr. Reddy's In Testosterone Gel Patent Suit
- Creditors Fight SIGA's Bid To Maintain Control Of Ch. 11
- J&J Found Liable In 3rd Risperdal Breast-Growth Case
- Texan Says 3M Device Led to Infection, Amputation
- Will Changes To Federal Rules Reduce Scope Of Discovery?
- A Closer Look At Ariosa After Fed. Circ. Denies Rehearing
- TriReme Loses $4.7M Fee Bid After Heart Catheter Trial Win
- Philly Jury Urged To Find Against J&J In Breast-Growth Case
- Jury Clears Ga. Man Of Insider Trading In Sanofi Case
- AstraZeneca Says Amneal Infringed Diabetes Drug Patents
- Biotech Wants Answers On Ex-GC's Role In Securities Scheme
- Gilead Pushes Court To Invalidate 2 Merck Drug Patents
- 2 Life Science Cos. Pull IPOs Over Weak Market Conditions
- DC Circ. Tosses Watson's Appeal Of Vascepa FDA Remand
- The Art Of The Mock
- Apotex Biosimilar Notice To Amgen Is Mandatory, Judge Says
- Drug Cos. Ask Court To Delay Decision Over Aggrenox Market
- Faster Generics Approval Could Cut Drug Costs, Senate Told
- Chancery Cuts Attys' Fees In Celgene Director Pay Deal
- Patents Not Sunk By Invalidation Of Some Claims, Judge Says
- PTAB Urged To Nix Reviews Sought By Bass-Affiliated Group
- Wholesale Drug Distributor Charged In $100M Fraud Scheme
- Baker & McKenzie Adds IP Litigator From Ropes & Gray
- AstraZeneca, Palmetto End Crestor Patent Fight
- Bass Loses Bid To Nix 'Ridiculous' Arthritis Drug Patent
- Strategies For Your Evolving Law Department
- CORRECTED: Teva Copaxone Patent Upheld As Valid By EPO
- Supplement Co. In Wal-Mart False Ad Row Wants Sanctions
- FDA Warning Wire: 'Life-Threatening' Compounder Supplies
- FedEx Wants To Know Drug Shipping Grand Jury Instructions
- Consumers Push For Judgment In Muscle Milk Ad Suit
- Del. Co. In Default In Pharma Dispute With Swiss Co.
- Judge Recuses Self In Suit Over DePuy Pinnacle Hip Implant
- Orthofix Reaches $11M Settlement in Securities Action
- Takeda, AstraZeneca Sue Apotex Over Generic COPD Drug
- The Unfortunate Fall Of The IPXI Marketplace
- GCs Love These Firms More And More
- Takeda Asks 9th Circ. To Act Before Tribal Trial In Actos Suit
- GCs Name Most Arrogant Law Firms
- 5 Firms Make It Back Onto GCs' Most Adored List
- 3 Firms Know The Secret To Keeping Clients Happy
- Specialty Pharmacy Can't Keep Express Scripts Contract
- Arbitration Required In $6M Breach Suit, Pharma Co. Says
- Fed. Circ. Urged To Revive 'Inventive' DNA Patent
- Judge Postpones Stent IP Trial Between WL Gore and CR Bard
- Illumina Urges Fed. Circ. To Reinstate Sequencing Patent
- Ethicon Official In Pa. Mesh Trial Defends Product's Safety
- False Claim Not Apparent To 2nd Circ. In Lipitor Suit
- All Camps Agree: Memorable Biosimilar Names Are A Must
- AstraZeneca, Others Must Expand Diabetes Drug Warnings
- Where Common Law Litigation And Int'l Arbitration Divide
- Girardi Keese Asks Justices To Nix $10M Avandia Fee Sharing
- 6th Circ. Vacates Ex-Atty's Sentence Over Fen-Phen Fraud
- Galena To Pay $20M To End Investor Suits Over Deceptive PR
- Ethicon Safety Commitment Questioned In Pa. Mesh Trial
- Unions Tell Obama That TPP Will Lower Living Standards
- St. Jude Gets Wireless Communications Patent Claims Nixed
- AbbVie, Endo Deceived Men About Testosterone Gel, Suit Says
- Brazil Raids Medical Device Cos. On Antitrust Worries
- UCB Awarded $6M In Fees In Apotex Infringement Suit
- AbbVie Sues Sandoz Over Testosterone Gel Patents
- Taxation With Representation: Wachtell, Skadden, Latham
- Quick Win For Drug Cos. Unlikely In Testosterone Therapy MDL
- J&J Says Mother's Testimony Not Worth $2.5M Risperdal Award
- Mylan Latest To Feel DOJ Heat Over Generics Price Hikes
- Pfizer Seeks To Toss Zoloft Birth Defects MDL
- Perfect Surgical Asks Fed. Circ. To Revive Claims On 2 Patents
- 3 Takeaways From The DOJ's $3.6B FCA Haul
- Senate Votes To Repeal Key ACA Provisions
- Gore Stent Graft Patents' Validity, Definiteness Upheld
- Medtronic Crushes Lenox Bone Mill Antitrust Row
- Deals Rumor Mill: Staples, Royal Dutch Shell, Teva
- FDA Pushes Final Generic Labeling Rule To July
- 5 Tips To Avoid Spoliation Sanctions
- Ill.'s Medicaid Prescription Cap Challenged In 7th Circ.
- AstraZeneca Defends NJ Venue In Breast Cancer Drug Row
- Life Sciences MVP: White & Case's Jack Pace
- XBiotech Faces Class Action Over Drug Study Problems
- Pfizer Wins Exclusion Of Zoloft Birth Defect Testimony
- The Unrealized Promise Of Rule 26 Amendments
- Bayer Gets 10 Cases Tossed From Mirena Defect MDL
- Fed Circ. Affirms Nixing Of Claims In Hill-Rom's Bed Patent
- Ethicon Can't Duck Patients' Defect Claims In Mesh MDL
- How GlaxoSmithKline Forced Its Firms To Think Differently
- Boston Scientific, Bard Must Pay For Mesh Injury, Jury Told
- Life Sciences MVP: Sullivan's Krishna Veeraraghavan
- FDA Orders Dietary Products Pulled Over Synthetic Drug
- Investor Classes Certified In SAC Capital Insider Trading Suit
- Mass Tort Status Sought For Cipro, Avelox, Levaquin Cases
- White House Threatens Veto Of ACA Repeal Bill
- GNC Facing Another Class Action Over 'Spiked' Supplements
- Pelvic Mesh Caused Irreversible Conditions, Pa. Jury Hears
- IP Firm Wolf Greenfield Adds Ex-Locke Lord Atty As Partner
- What To Expect From HHS Inspector General Next Year
- Full Fed. Circ. Won't Rehear Fetal DNA Patent Row
- FDA Warning Wire: Nvision, Compounders, Drugged Meat
- Senate Forges Ahead With Effort To Repeal ACA
- Sens. Unveil Huge Stash Of Gilead Drug-Pricing Records
- Lupin Says 'Sensitive' Docs Are Irrelevant In Paxil Fight
- Homeopathic Co. Says Evidence Still Missing In False Ad Suit
- Life Sciences MVP: Sullivan & Cromwell's Matt Hurd
- Montel-Endorsed Apparel Co. Settles FTC Suit For $1.4M
- Glaucoma Drug Co. Says Investor Suit 'Makes No Sense'
- Bass, Spangenberg Target Diprivan Patent In AIA Review
- A Close Look At The Latest Anti-Inversion Guidance
- Defending 'Salt Patents' In Hatch-Waxman Cases
- Making The Most Of Document Analytics